N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne™ 64-Gene Oncology Panel
- Posted by Emily Haynes
- On April 12, 2016
- 0 Comments
LEXINGTON, Mass., April 12, 2016 – N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, today announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.
The OncoGxOne™ is a next-generation sequencing (NGS) panel that detects 64 of the most common mutated genes found in several cancer types. Mutation types detected include single nucleotide variants, insertions and deletions, copy number variants and gene fusions associated with all current FDA approved targeted therapies and multiple registered clinical trials. Results are delivered in an easy to interpret report providing physicians with the information necessary to practice precision medicine in a cost-efficient manner.
N-of-One clinical interpretation provides high-quality analysis of the results of each OncoGxOne™ test, identifying the most relevant therapeutic options for each patient based on the scientific and clinical evidence.
“We are very pleased to be able to offer N-of-One’s patient-specific analysis with our OncoGxOne™ cancer panel,” said James Dermody, Ph.D., Admera Health Lab Director. “Admera Health’s goal of easily integrating into routine clinical practice is supported by partnering with N-of-One. With N-of-One, we can provide oncologists with an Admera Health diagnostic report that is clear, actionable, and based on the latest scientific evidence. We are confident that we can quickly and efficiently provide the very best reports to our customers, so that they can provide the best care possible to their patients.”
“N-of-One is excited to be working with Admera Health to deliver a best-in-class, patient-specific solution to the market,” said Chris Cournoyer, CEO at N-of-One. “Our objective is to continue to provide the highest quality clinical interpretation to enable clinicians to reap the most value from Admera Health’s OncoGxOne™ panel. Ultimately, the patients and their physicians gain the greatest benefit from our working together.”
About Admera Health
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results, please visit www.admerahealth.com.
N-of-One is the leader in providing patient-specific therapeutic options for precision medicine in oncology by leveraging its world-class team of practicing oncologists and Ph.D. scientists. The N-of-One team, coupled with proprietary technology and processes, enables N-of-One to analyze molecular diagnostic tests required to utilize this data at the point of care. Using N-of-One, laboratories can scale their molecular diagnostic programs with the highest quality clinical interpretation while still saving time and money. N-of-One’s team of experts has provided therapeutic options including clinical trials to client organizations for thousands of patient cases across hundreds of cancer types. N-of-One partners with leading diagnostic companies, hospital systems, and also provides services through employee access benefit programs. N-of-One does not provide medical services, nor is any N-of-One employee engaged in the practice of medicine for or on behalf of N-of-One. For more information, please visit www.n-of-one.com or call 617-202-9808.